Vicore Pharma Gets FiMea Cleranes for Phase I Study with C21
Thursday, April 14, 2016
Vicore Pharma Holding AB Said on Thursday had received clearance from FiMea, the Finish Medicines Agency, to start clinical Phase I study with drug candidate C21.
Study, which is to commence in few weeks, will be carried out at Clinical Research Turku Services (CRST) in Åbo, Finland.
Phase I study will be a double blind, randomized, placebo-controlled study of orally administrated C21 with aim to evaluate safety and tolerability of escalating doses.
Final rapport from multiple doses in expected in Q4.
Source : reuters.com
